+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID05306041

Randomized Phase II Study of Neoadjuvant Endocrine Therapy with Pertuzumab-Trastuzumab Combination With or Without Inavolisib in HER2-positive, HR-positive, PIK3CA Mutant Early Breast Cancer

Led by GBG Forschungs GmbH · Updated on 2026-09-11

170

Participants Needed

62

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the potential added benefits and safety of the drug inavolisib when combined with neoadjuvant endocrine therapy in patients with early-stage HER2-positive, hormone receptor-positive, PIK3CA mutant breast cancer. This phase II, randomized, open-label study aims to compare the effects of endocrine therapy plus dual anti-HER2 treatment with or without inavolisib, focusing on how well these treatments work before surgery. Participants will be randomly assigned to one of two groups one receiving daily inavolisib along with endocrine therapy and a fixed-dose combination of pertuzumab and trastuzumab given subcutaneously every three weeks for six cycles 18 weeks, and another group receiving the same endocrine therapy and anti-HER2 treatment without inavolisib. Endocrine therapy may include tamoxifen or an aromatase inhibitor, with or without a GnRH analogue for premenopausal women and men. Treatment continues until surgery, disease progression, unacceptable side effects, or patient withdrawal. During the study, participants will undergo surgery or biopsy after completing the treatment to assess the pathologic complete response rate in the breast and lymph nodes. Researchers will also monitor tumor response through physical exams and imaging, track safety and tolerability, evaluate the need for additional chemotherapy, and follow long-term outcomes such as disease-free and overall survival for up to five years. The study involves regular assessments, laboratory tests, and monitoring to understand treatment effects and safety.

CONDITIONS

Brief Title

Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer

Research Team

J

Jana Roßney

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here